Abstract
Introduction
Systemic sclerosis (SSc) is associated with interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH). This study aimed to explore the prevalence, clinical features, hemodynamic characteristics and prognosis of different severity of ILD in a cohort of patients with SSc-associated precapillary pulmonary hypertension (SSc-PH) and investigate the differences between SSc-PAH and idiopathic pulmonary arterial hypertension (IPAH) patients.
Method
SSc-PH patients and IPAH patients, admitted to Shanghai Pulmonary Hospital (August 1, 2008–January 31, 2020) and diagnosed by right-sided heart catheterization (RHC) or echocardiography, were retrospectively included. SSc-PH patients had a baseline chest high-resolution computed tomography (HRCT), and PH classification was based on the extent of ILD. Clinical, pulmonary function, hemodynamic characteristics and survival data were extracted.
Results
The study included 45 SSc-PH patients (60% had coexisting ILD and 77.8% were SSc-Group 1 PH/SSc-PAH [without ILD or with mild ILD], 22.2% were SSc-Group 3 PH/SSc-PH with severe ILD) and 52 IPAH patients. SSc-PH with ILD had lower arterial oxygen partial pressure (PaO2) than those without ILD. Hemodynamic characteristics and survival rates were comparable between SSc-PAH with mild ILD and those without ILD. SSc-Group 3 PH had lower pulmonary vascular resistance (PVR) and more severe restrictive ventilatory dysfunction than SSc-Group 1 PH, but the survival rate was equally poor. SSc-PAH had a poorer prognosis than IPAH patients despite the better hemodynamic characteristics.
Conclusions
ILD was common in SSc-PH patients. Careful phenotyping of PH in SSc-PH patients is very important as it is imperative to recognize its impact on clinical course, treatment and survival.
Key Points
• ILD was common in Chinese SSc-PH patients.
• SSc-PH patients with ILD had lower PaO 2 than those without ILD.
• Hemodynamic characteristics and survival rates were similar in SSc-PAH patients with mild ILD and those without ILD.
• Patients in SSc-Group 3 PH had lower pulmonary vascular resistance (PVR) and more severe restrictive ventilatory dysfunction than those in SSc-Group 1 PH, but the survival rate was equally poor. SSc-PAH patients had a poorer prognosis than IPAH patients despite their better hemodynamic characteristics.
Similar content being viewed by others
References
Pattanaik D et al (2015) Pathogenesis of systemic sclerosis Front Immunol 6:272
Sticherling, M., Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges, 2012. 10(10): p. 705–18; quiz 716.
Ferri C et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139–153
Elhai M et al (2017) Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis [12]76(11):1897–1905
Poudel DR et al (2018) Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int 38(10):1847–1858
Simeon-Aznar CP et al (2015) Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death. Medicine (Baltimore) 94(43):e1728
Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66(7):940–944
Galie N et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975
Simonneau G et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-41
Hoeper MM et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42-50
Le Pavec J et al (2011) Scleroderma lung disease. Clin Rev Allergy Immunol 40(2):104–116
Launay, D., et al., Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev 2017. 26(145).
Chaisson NF, Hassoun PM (2013) Systemic sclerosis-associated pulmonary arterial hypertension. Chest 144(4):1346–1356
Becker MO, Riemekasten G (2016) Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol 12(2):115–135
Mukerjee D et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093
Chung L et al (2014) Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) 66(3):489–495
Lefevre G et al (2013) Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 65(9):2412–2423
Tyndall AJ et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815
Fisher MR et al (2006) Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54(9):3043–3050
Kawut SM et al (2003) Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123(2):344–350
van den Hoogen F et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747
Travis WD et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748
Goh NS et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254
Santosa A et al (2016) Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. Scand J Rheumatol 45(6):499–506
Bauer PR et al (2013) Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 144(2):571–577
Launay D et al (2006) High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 33(9):1789–1801
Nihtyanova SI et al (2014) Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 66(6):1625–1635
Pope JE et al (2005) Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 32(7):1273–1278
Avouac J et al (2010) Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 37(11):2290–2298
Condliffe R et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179(2):151–157
Hinchcliff M et al (2011) Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 38(10):2172–2179
Coghlan JG et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349
Michelfelder M et al (2017) Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol 36(2):381–390
Launay D et al (2018) Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS One 13(5):e0197112
Goh NS et al (2017) Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 69(8):1670–1678
Young A et al (2019) Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis. Arthritis Rheumatol 71(8):1339–1349
Seeger W et al (2013) Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62(25 Suppl):D109–D116
Hachulla AL et al (2009) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 68(12):1878–1884
Hachulla E et al (2009) Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 136(5):1211–1219
Fischer A et al (2014) Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 32(6 Suppl 86):S-109-14
Chung L et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138(6):1383–1394
Clements PJ et al (2012) The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 71(2):249–252
Meune C et al (2010) Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 103(1):46–52
Follansbee WP et al (1990) A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 17(5):656–662
Funding
This study was supported by the Programme of the National Natural Science Foundation of China (81900050, 81870042 and 81700045), the Youth Project of Shanghai Municipal Commission of Health and Family Planning (20174Y0143), the National Science and Technology Information System of the People’s Republic of China (2018YFC1313603) and the National Health and Family Planning Commission of the People’s Republic of China (2015BAI12B10). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Ethics approval
This study was approved by the ethics review committee of Shanghai Pulmonary Hospital, which waived the requirement for informed consent due to the retrospective study design.
Disclosures
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ping Yuan and Yi-Liang Su are co-first authors.
Rights and permissions
About this article
Cite this article
Yuan, YP., Yuan, P., Su, YL. et al. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study. Clin Rheumatol 41, 1675–1686 (2022). https://doi.org/10.1007/s10067-021-06016-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-021-06016-8